Grant: CIHR Fellowship
Direct Payment
$100,000.00
Targeting DNA repair mechanisms in cancer - developing inhibitors of Nudix proteins: NUDT1, NUDT5 and NUDT15 as cancer therapeutic agents
EF 2012-13
Résumé
Despite advances in cancer treatment, cancer is a leading cause of death in Canada and will kill more than 75 000 Canadians this year. The search for new cancer treatments is a key for limiting the impact of this disease and saving lives. A newly established avenue for the development of cancer therapeutics is targeting DNA repair mechanisms.
Due to changes in how they generate energy, cancer cells produce large amounts of damaged nucleoside bases, which are the main building block of DNA. If damaged nucleosides are incorporated into DNA, the cell recognizes that the DNA is damaged and it will self destruct. To overcome this, cancer cells have robust DNA repair mechanisms that prevent damaged nucleoside bases from being used in DNA synthesis.
We have recently discovered that members of the Nudix family of proteins are involved in DNA repair and are critically important for cancer cell survival. Conversely, healthy cells have very low levels of damaged nucleosides and thus, inhibiting Nudix proteins in healthy cells will have minimal effect.
The proposed research aims to develop inhibitors of Nudix proteins as cancer therapeutic agents. This will be done by screening large libraries of potential inhibitors against purified Nudix proteins, then using medicinal chemistry techniques to develop these inhibitors into better drug candidates. These potential drugs will be examined in a panel of different cancers with a particular focus on breast and hematological cancers. It is hoped that these novel inhibitors will provide a new and valuable weapon to be used in the fight against cancer.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Sweden
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
269492
Name
Page Brent
Country
Sweden
Orgtype
Research Institution
Partnername
Breast Cancer Society of Canada (North Sarnia, ON)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Targeting DNA repair mechanisms in cancer - developing inhibitors of Nudix proteins: NUDT1, NUDT5 and NUDT15 as cancer therapeutic agents
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Anti-Cancer Drugs; Blood Cancer; Breast Cancer; Combination Therapies; Dna Repair; Drug Design; Drug Development; Drug Discovery; Medicinal Chemistry; Structure Activity Relationship
Abstract
Despite advances in cancer treatment, cancer is a leading cause of death in Canada and will kill more than 75 000 Canadians this year. The search for new cancer treatments is a key for limiting the impact of this disease and saving lives. A newly established avenue for the development of cancer therapeutics is targeting DNA repair mechanisms.
Due to changes in how they generate energy, cancer cells produce large amounts of damaged nucleoside bases, which are the main building block of DNA. If damaged nucleosides are incorporated into DNA, the cell recognizes that the DNA is damaged and it will self destruct. To overcome this, cancer cells have robust DNA repair mechanisms that prevent damaged nucleoside bases from being used in DNA synthesis.
We have recently discovered that members of the Nudix family of proteins are involved in DNA repair and are critically important for cancer cell survival. Conversely, healthy cells have very low levels of damaged nucleosides and thus, inhibiting Nudix proteins in healthy cells will have minimal effect.
The proposed research aims to develop inhibitors of Nudix proteins as cancer therapeutic agents. This will be done by screening large libraries of potential inhibitors against purified Nudix proteins, then using medicinal chemistry techniques to develop these inhibitors into better drug candidates. These potential drugs will be examined in a panel of different cancers with a particular focus on breast and hematological cancers. It is hoped that these novel inhibitors will provide a new and valuable weapon to be used in the fight against cancer.
Competitiondate
201210
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Page, Brent
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~